Orientin protects pancreatic beta-cells from STZ-induced damage by modulating oxidative stress, inflammation, apoptosis, and pyroptosis.

Type 1 Diabetes (T1D) is a severe autoimmune disorder characterized by the destruction of pancreatic beta-cells, leading to insulin deficiency. Current treatments primarily focus on insulin replacement, but strategies to preserve residual beta-cell mass or prevent further destruction are urgently needed. Oxidative stress and chronic inflammation are key drivers of beta-cell demise in T1D pathogenesis. Flavonoids like Orientin, known for their antioxidant and anti-inflammatory properties, offer a promising avenue for therapeutic intervention by potentially mitigating these damaging processes and preserving beta-cell integrity.

Researchers investigated Orientin's protective effects in 42 mice with streptozotocin (STZ)-induced type 1 diabetes (induced by a single intraperitoneal injection of 160 mg/kg STZ). Mice were divided into seven groups, including control and STZ-diabetic groups, with Orientin treatment arms. Proinflammatory (IL-1β, IL-6) and anti-inflammatory (TGF-β, IL-10) cytokines were measured via ELISA. Pancreatic tissues underwent histopathological analysis and immunohistochemistry for NF-κB p65. Oxidative stress parameters (SOD, CAT, GSH, MDA) were assessed in both pancreatic and hepatic tissues. In vitro, the study evaluated Orientin's protection against STZ-induced damage in pancreatic Beta-TC6 cells, analyzing apoptotic markers (Caspase-3, Caspase-9, Bax, Bcl-2) by immunohistochemistry and pyroptotic markers (IL-1β, Caspase-1) by ELISA.